A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED ENDPOINT EVALUATION, PHASE 3 STUDY COMPARING THE EFFECT OF ABELACIMAB RELATIVE TO APIXABAN ON VENOUS PIXABAN ON VENOUS THROMBOEMBOLISM (VTE) RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER ASSOCIATED VTE (ASTER)

Registry ID

ANT-007

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ANTHOS THERAPEUTICS, INC.

Start date

2023-08-24

Last update

2022-01-07

Conditions

• VENOUS THROMBOEMBOLISM

Related clinical trials

• THE PARTUM (POSTPARTUM ASPIRIN TO REDUCE THROMBOEMBOLISM UNDUE MORBIDITY) TRIAL
• A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL STUDY OF REGN9933, A FACTOR XI MONOCLONAL ANTIBODY, FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ELECTIVE, UNILATERAL, TOTAL KNEE ARTHROPLASTY
• PRIMARY THROMBOPROPHYLAXIS IN PATIENTS WITH MALIGNANCY AND CENTRAL VENOUS CATHETERS: A RANDOMIZED CONTROLLED TRIAL (TRIM-LINE)
• THE SAVER TRIAL: STATINS FOR VENOUS EVENT REDUCTION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
• A PILOT STUDY ASSESSING THE FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL EVALUATING ASPIRIN IN POSTPARTUM WOMEN AT RISK OF DEVELOPING VENOUS THROMBOEMBOLISM.
• LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT RECURRENT VTE IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL OF TWO DOSES

View on source registry